Exclusive copyright, patent, know how, process and technology cross-license to exploit, develop, research, manufacture, label, package, process, commercialize, promote, market, sell, distribute, import, export and sublicense the TAK-385 and TAK-448 products and chemical or oligopeptide compounds, to treat, prevent, cure or control symptoms of uterine fibroids, endometriosis or prostate cancer.

This document is a title for a license agreement rather than a research paper, detailing the cross-licensing of intellectual property for TAK-385 and TAK-448 products. The agreement grants rights to develop, manufacture, and commercialize these compounds for treating uterine fibroids, endometriosis, or prostate cancer. It is listed within RoyaltyStat, a database used by professionals for transfer pricing and intellectual property analytics. Relevance to endometriosis: listed as one indication for TAK-385 and TAK-448, though the paper's main focus is the legal and financial terms of the license agreement.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works